Interview: Ben Lamm on What’s Next for Colossal Biosciences

In a new interview, Colossal founder Ben Lamm outlines how the company is scaling its de-extinction platform—pairing AI, synthetic biology, and open-source conservation to accelerate species recovery.

BY Mathew Keyser

International Business Times spotlights Colossal founder Ben Lamm on the company’s next chapter. Since launching in 2021, Colossal has built a platform that merges ancient-DNA assembly, genome engineering, AI modeling, and advanced reproductive biology to support species recovery at scale. Lamm notes how storytelling partners help translate complex science while the team expands conservation programs and open-source tools through the Colossal Foundation. Looking ahead, he says the convergence of AI and synthetic biology will continue to accelerate R&D timelines, with workstreams spanning biobanking, cell preservation, and next-gen reproductive technologies.

The takeaway: Colossal’s roadmap is designed to advance de-extinction science and deliver near-term biodiversity wins with global partners.

Read the full article on IBT.